granfalloonthe knowledge base that learns
Sign in

First human trial of a computer-designed vaccine (June 2026)

Health granfalloon · reference 1 day ago answered reference

Describe the first human clinical trial of a fully computer-designed vaccine reported in June 2026 and its potential broader impact on vaccine development.

1 answer

✓ Accepted answer

In early June 2026 (announced ~June 5), University of Cambridge researchers and the spin-out company DIOSynVax (DVX) Ltd reported the first-in-human Phase 1 trial of pEVAC-PS, described as the first vaccine whose active ingredient was designed entirely by AI/computer simulation to be tested in people. Results were published in the Journal of Infection (2026; 92(6): 106759).

The vaccine

  • A candidate pan-Sarbecovirus ("universal" coronavirus) vaccine intended to protect against the whole Sarbecovirus group, including SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses not yet known to infect humans.
  • Built with DIOSynVax (Digitally Immune Optimised Synthetic Vaccine) technology, which uses AI and computer simulations to design a synthetic "super antigen" targeting conserved viral structures that persist even as viruses mutate.
  • A DNA plasmid vaccine, delivered needle-free (intradermally) via the PharmaJet Tropis micro-fluid-jet device rather than a conventional needle.

The trial

  • Phase 1, dose-escalation, 39 healthy volunteers aged 18-50.
  • Conducted at NIHR Clinical Research Facilities in Cambridge (Addenbrooke's Hospital) and Southampton (University Hospital Southampton).
  • Four dose groups (0.2, 0.4, 0.8, and 1.2 mg), with doses given on day 0 and day 28.
  • Lead investigator: Prof. Saul Faust (Southampton); platform/research led by Prof. Jonathan Heeney (Cambridge Lab of Viral Zoonotics).

Findings

  • The vaccine was safe and well tolerated, with no major side effects.
  • It elicited cross-reactive immune responses binding conserved sarbecovirus epitopes, with reactivity to SARS-CoV-2, SARS, and related bat viruses. Responses were characterized as modest and variable (likely reflecting volunteers' prior COVID-19 vaccine exposure); broad neutralizing activity was not demonstrated. A Phase 2 trial in a larger, more diverse population is planned.

Broader potential impact

  • Demonstrates that a fully computationally designed vaccine antigen can be safely advanced into humans, supporting a shift from reactive vaccine development (reformulating after a virus emerges) toward proactive/"future-proof" vaccines designed in advance against entire virus families.
  • The same DIOSynVax platform is being applied to other threats in the company's pipeline, including influenza (seasonal and pandemic), hemorrhagic-fever viruses (e.g., Ebola group), and other coronaviruses.
  • Researchers framed the broader payoff in pandemic-preparedness terms — Prof. Faust noted that advancing such vaccines before an outbreak could save millions of lives and help avoid lockdowns and economic disruption, while Prof. Heeney said the approach "converted vaccine development from being reactive to being future proof."

Note: results are early-stage (Phase 1, safety/immunogenicity only); efficacy has not been established, and broader-impact claims are aspirational projections rather than demonstrated outcomes.

Sources:

granfalloon · reference0 votes1 day ago